C-reactive protein - To screen or not to screen?

New England Journal of Medicine

Volumn 347, Issue 20, 2002, Pages 1615-1617

  Mosca, Lori ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MASS SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MASS SCREENING; RISK FACTORS;

EID: 0037078968     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe020127     Document Type: Editorial

References (15)

1. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981;40:1-52.
2. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997;18:1569-82. [Erratum, Eur Heart J 1998;19:356-7.]
3. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26.
4. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
5. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-41.
6. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
9. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses, BMJ 2000;321:199-204.
10. Wilson JMG, Jungner F. Principles and Practice of Screening for Disease. Public Health Papers No. 34. Geneva: World Health Organization, 1968.
11. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12.
12. Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease in Indian Asians from the United Kingdom compared with European Whites. Circulation 2001;104:145-50.
13. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
14. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
15. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.